1 / 14

ALOXI MORE COST EFFECTIVE THAN ZOFRAN!

ALOXI MORE COST EFFECTIVE THAN ZOFRAN!. Presented By: Julie Hoffman, ADN, RN, OCN Sylvia Wentzky, ADN, RN Bon Secours St. Francis Health System Greenville, South Carolina. PURPOSE:.

lynton
Download Presentation

ALOXI MORE COST EFFECTIVE THAN ZOFRAN!

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ALOXI MORE COST EFFECTIVE THAN ZOFRAN! Presented By: Julie Hoffman, ADN, RN, OCN Sylvia Wentzky, ADN, RN Bon Secours St. Francis Health System Greenville, South Carolina

  2. PURPOSE: The purpose of this Evidence Based Project was to compare the cost effectiveness of two anti-nausea medications: ALOXI and ZOFRAN for patients receiving highly emetogenic chemotherapy regimens, such as Cisplatin.

  3. MATERIALS & METHODOLOGY: • Bon Secours St. Francis Health System Outpatient Infusion Center • Retrospective 3 month chart review • Solid tumor types • 100 adult patients

  4. DATA POINTS COLLECTED: • Gender • Age • Diagnosis • Types of Lung Cancer Treatments • Antiemetics in Cisplatin Protocols

  5. RESULTS: Aloxi: • IV push 1 dose day of chemo • Nursing time -5 minutes • Supplies – needle & syringe Zofran: • IVPB treatment day • 2 extra days of IV fluids and daily Zofran IVPB • Nursing time – 6.5 hours • Supplies – IV tubing ALOXI- 8% Total Cost Savings Increased Patient Satisfaction Decreased Nursing Time ZOFRAN- Lower Patient Satisfaction Increased Clinic Visits Increased Nursing Time

  6. CONCLUSION: The cost analysis demonstrated that selecting Aloxi on Day 1 of the chemotherapy treatment impacted: • Cost • Patient Satisfaction • Nurse Time Limitations of this study included a small sample size, retrospective nature, and selective diagnosis of Lung Cancer.

  7. UPDATE: • Product Availability • Provider Changes & Preferences • Protocol Changes • Dexamethasone 10 mg IVP • Zofran 8 mg IVP • Emend 150 mg IVPB • 3 Month Retrospective Analysis (2014) • 12 Lung Cancer Patients – Cisplatin Treatment • 1 Patient Needed Hydration

  8. REFERENCES: DeLeon, A. (2006, October). Palonosetron (Aloxi): A Second Generation 5HT3 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting. Baylor University Medical Center Proceeding, 19(4),413-416. Retrieved from http:///www.medscapecom/viewarticle/512796 Feinberg, B.A., Gilmore, J., Haislip, S., Gondesen, T., Saleh, N., Lenz, W. (2009, February). Data-Driven Medical Decision-Making in Managing Chemotherapy-Induced Nausea and Vomiting, Community Oncology, 62-67. Retrieved from http://www.CommunityOncology.net National Comprehensive Cancer Network. (2011). NCCN Clinical Practice Guilelines in Oncology (NCCN Guidelines) Antiemesis(Version 1.2012). Fort Washington, PA: Ettinger, David S., et al. Tarricone, R., & Girolami, F. (2005). Economic Evaluation of a New Antiemetic Drug – Palonosetron Versus Ondansetron, Clinical Drug Investiation, 25 (9), 597-608 Retrieved from http://www.nci.nlm.nih.gov/pmc/articles/PMC1618755

  9. Bon Secours St. Francis Health System Outpatient Infusion Center Greenville, South Carolina JULIE HOFFMAN, ADN, RN, OCN JULIANA_HOFFMAN @BSHSI.ORG SYLVIA WENTZKY, ADN, RN SYLVIA_WENTZKY@BSHSI.ORG TRACY FASOLINO, PhD, FNP, ACHPN TRACY_FASOLINO@BSHSI.ORG

More Related